Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > Corporate Overview - May 2023
View:
Post by Speyeder999 on Jun 15, 2023 8:18pm

Corporate Overview - May 2023

https://d1io3yog0oux5.cloudfront.net/_f34c61df68d6619194d97a763502e5cd/promisneurosciences/db/933/8787/pdf/PMN+Corp+Deck_Final_08May23.pdf

Although I do truly appreciate the regular corporate overview updates, one has to wonder what purpose they serve when certain stated milestones have yet to transpire. Does anyone proof read this before its released?


slide 22 -   ''Data expected to be available mid-2023''      really? 
 
slide 25 -   ''On track for Phase 1a first subject visit 1H2023''    again, really? 

slide 15 -    ''PMN310 Clinical data starting in 2023''       Oh, ok (so much clearer now)

slide ??? -  ''Required Financing to make all this happen''
Comment by BottomBroker on Jun 16, 2023 2:07pm
Have to admit, I've lost a lot of confidence and trust in PMN. Might be a glimmer of hope left, but even that's fading. 
Comment by M101 on Jun 16, 2023 4:18pm
It's wearing on me too, but I put myself in the shoes of the Boston Group and this situation suits me fine.  104 shareholders sounds like a private company already but maybe half that is even better for those with deep pockets. Time also lets warrants expire out of the money.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities